OPTIMAL LYMPHOCYTIC CHORIOMENINGITIS VIRUS SEQUENCES RESTRICTED BY H-2D(B) MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I MOLECULES AND PRESENTED TO CYTOTOXIC T-LYMPHOCYTES

被引:106
作者
GAIRIN, JE [1 ]
MAZARGUIL, H [1 ]
HUDRISIER, D [1 ]
OLDSTONE, MBA [1 ]
机构
[1] CNRS, PHARMACOL & TOXICOL FONDAMENTALES LAB, F-31077 TOULOUSE, FRANCE
关键词
D O I
10.1128/JVI.69.4.2297-2305.1995
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Infection with lymphocytic choriomeningitis virus induces the generation of CD8(+) cytotoxic T lymphocytes (CTL). In the H-2(b) mouse, this cellular immune response is directed against three viral structural epitopes (GP1, GP2, and NP) presented by the major histocompatibility complex (MHC) class I H-2D(b) molecules. This study was undertaken to delineate which sequence of each of these three epitopes is optimal for MHC binding and CTL recognition. The first step was to synthesize the relevant peptides truncated at the N or C terminus and flanking the crucial H-2D(b)-anchoring Asn residue in position 5. These peptides were then tested (i) for their binding properties in two H-2D(b)-specific assays with viable cells (upregulation of H-2D(b) expression on the surface of RMA-S cells and competition against the D-b-restricted peptide I-125-gp276-286 on T2-D-b cells) and (ii) for their abilities to sensitize H-2(b) target cells for CTL lysis in vitro. For optimal antigenic presentation, all three epitopes required the MHC-anchoring Asn residue at position 5 of their sequences. The results clearly and unambiguously delineated optimal lengths for two of the epitopes and two options for the third. NP appeared as a conventional 9-amino-acid (aa)-long peptide, np396-404 (FQPQNGQFI). GP2 was defined as a longer peptide (11 aa), gp276-286 (SGVENPGGYCL). Characterization of the GPI epitope was more complex: the 9-aa-long peptide gp33-41 (KAVYNFATC) and the carboxyl-extended 11-aa-long peptide gp33-43 (KAVYNFATCGI) were both established as possible optimal sequences depending on the cell line used to test binding and lysis.
引用
收藏
页码:2297 / 2305
页数:9
相关论文
共 38 条
  • [1] ANDERSON KS, 1993, J IMMUNOL, V151, P3407
  • [2] BYRNE JA, 1984, J IMMUNOL, V133, P433
  • [3] PEPTIDE BINDING TO CLASS-I MHC ON LIVING CELLS AND QUANTITATION OF COMPLEXES REQUIRED FOR CTL LYSIS
    CHRISTINCK, ER
    LUSCHER, MA
    BARBER, BH
    WILLIAMS, DB
    [J]. NATURE, 1991, 352 (6330) : 67 - 70
  • [4] MUTATIONS THAT IMPAIR A POSTTRANSCRIPTIONAL STEP IN EXPRESSION OF HLA-A AND HLA-B ANTIGENS
    DEMARS, R
    RUDERSDORF, R
    CHANG, C
    PETERSEN, J
    STRANDTMANN, J
    KORN, N
    SIDWELL, B
    ORR, HT
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (23) : 8183 - 8187
  • [5] PEPTIDE SELECTION BY CLASS-I MOLECULES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX
    ELLIOTT, T
    SMITH, M
    DRISCOLL, P
    MCMICHAEL, A
    [J]. CURRENT BIOLOGY, 1993, 3 (12) : 854 - 866
  • [6] STRUCTURE OF PEPTIDES ASSOCIATED WITH MHC CLASS-I MOLECULES
    ENGELHARD, VH
    [J]. CURRENT OPINION IN IMMUNOLOGY, 1994, 6 (01) : 13 - 23
  • [7] IDENTIFICATION OF NATURALLY PROCESSED VIRAL NONAPEPTIDES ALLOWS THEIR QUANTIFICATION IN INFECTED-CELLS AND SUGGESTS AN ALLELE-SPECIFIC T-CELL EPITOPE FORECAST
    FALK, K
    ROTZSCHKE, O
    DERES, K
    METZGER, J
    JUNG, G
    RAMMENSEE, HG
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (02) : 425 - 434
  • [8] ALLELE-SPECIFIC MOTIFS REVEALED BY SEQUENCING OF SELF-PEPTIDES ELUTED FROM MHC MOLECULES
    FALK, K
    ROTZSCHKE, O
    STEVANOVIC, S
    JUNG, G
    RAMMENSEE, HG
    [J]. NATURE, 1991, 351 (6324) : 290 - 296
  • [9] CRYSTAL-STRUCTURES OF 2 VIRAL PEPTIDES IN COMPLEX WITH MURINE MHC CLASS-I H-2K(B)
    FREMONT, DH
    MATSUMURA, M
    STURA, EA
    PETERSON, PA
    WILSON, IA
    [J]. SCIENCE, 1992, 257 (5072) : 919 - 927
  • [10] DESIGN OF HIGH-AFFINITY MAJOR HISTOCOMPATIBILITY COMPLEX-SPECIFIC ANTAGONIST PEPTIDES THAT INHIBIT CYTOTOXIC LYMPHOCYTE-T ACTIVITY - IMPLICATIONS FOR CONTROL OF VIRAL DISEASE
    GAIRIN, JE
    OLDSTONE, MBA
    [J]. JOURNAL OF VIROLOGY, 1992, 66 (11) : 6755 - 6762